How Trump and the FDA Can Create a Pharmaceutical Manufacturing Renaissance

In January, President Donald Trump said, “We have got to get our drug industry back.” Later that month, at a meeting in the Oval Office with executives of eight large innovator pharmaceutical companies, he said he wanted them to bring drug prices “way down,” and promised to curb regulations and lower tax rates to boost their competitiveness.

We are encouraged by these developments and consider these efforts as only the first steps by the president to understand the challenges of domestic pharmaceutical manufacturing. Furthermore, the nomination of Scott Gottlieb to lead the Food and Drug Administration adds to our encouragement. Gottlieb was the at the FDA during the time when the FDA launched its initiative the Pharmaceutical CGMPs for the 21st Century. To that end, we offer some points to consider in efficiently catalyzing a renaissance of a technologically modern, efficient, high quality, and profitable pharmaceutical manufacturing in the United States.

 
Sign Up for Our Email Newsletter

RECENT NEWS

Streamline drug approval process

Streamline drug approval process

When Americans don't fill their prescriptions, their illnesses worsen, which drives up healthcare spending....  Read more

‘Transparency’ alone can’t convey the context or complexity of pricing drugs

‘Transparency’ alone can’t convey the context or complexity of pricing drugs

A key problem with Mr. Azar’s transparency effort is that it doesn’t provide consumers with any context or insights into ...  Read more

Safe Harbor Sunshine And Flat Fees: Vital Steps Towards Smarter Drug Spending

Safe Harbor Sunshine And Flat Fees: Vital Steps Towards Smarter Drug Spending

The current system encourages payers to favor medicines that carry higher rebates than lower list-priced drugs....  Read more

DRUGWONKS BLOG